trending Market Intelligence /marketintelligence/en/news-insights/trending/VNlxcskBaSDCaaFLDDV3KQ2 content esgSubNav
In This List

Mereo BioPharma ovarian cancer therapy gets US FDA fast-track status

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Mereo BioPharma ovarian cancer therapy gets US FDA fast-track status

The U.S. Food and Drug Administration granted fast-track status to Mereo BioPharma Group PLC's navicixizumab to treat ovarian cancer.

SNL Image

London-based Mereo BioPharma is developing navicixizumab to treat high-grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least three prior therapies and/or before Roche Holding AG's Avastin.

The company added navicixizumab to its drug pipeline through the acquisition of oncology-focused biopharmaceutical company OncoMed Pharmaceuticals Inc.

Mereo BioPharma is evaluating navicixizumab, combined with chemotherapy drug paclitaxel, to treat patients with advanced heavily pretreated ovarian cancer in an ongoing phase 1b study.